Clinical trials: Digestive Disease
Primary Sclerosing Cholangitis
Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis
- Trial name
- NCT06886360
- Testing
- norucholic acid
- Volunteers
- 120 people
- Sponsor
- Dr. Falk Pharma GmbH
Primary Sclerosing Cholangitis
A Study of HTD1801 in Healthy Subjects
This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.
- Trial name
- NCT03099603
- Testing
- HTD1801
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Pancreatic Neoplasms
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer
A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.
- Trial name
- NCT00191568
- Testing
- Gemcitabine, Oxaliplatin, Radiotherapy
- Where
- 6 sites in France
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Hepatitis B
A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B
This is a local, prospective observational study (regulatory post marketing surveillance) to access the safety and effectiveness of Baraclude in Korean pediatric patients with chronic HBV infection who are between the ages of 2…
- Trial name
- NCT03426618
- Testing
- Non-interventional
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Liver Fibrosis, Cirrhosis
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
The purpose of this research study is to test the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced liver fibrosis and cirrhosis in patients with…
- Trial name
- NCT00043303
- Testing
- interferon gamma-1b
- Volunteers
- 502 people
- Sponsor
- InterMune
Bowel Disease
Study of NPO-13 During Colonoscopy
This study will investigate the safety, efficacy and dose-response of NPO-13 in subjects with moderate to severe colonic spasm during colonoscopy.
- Trial name
- NCT04097574
- Testing
- NPO-13: l-menthol
- Where
- 13 sites in Japan
- Volunteers
- 158 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Crohn's Disease
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition…
- Trial name
- NCT02048618
- Testing
- GLPG0634
- Where
- 63 sites in Belgium, Czechia and 7 more
- Volunteers
- 175 people
- Sponsor
- Lakefront Biotherapeutics NV
Healthy
Safety of Larazotide Acetate in Healthy Volunteers
To demonstrate the safety, tolerance and pharmacokinetics of multiple, oral doses of larazotide acetate.
- Trial name
- NCT00386490
- Testing
- larazotide acetate
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- 9 Meters Biopharma, Inc.
Breast Cancer, Colorectal Cancer
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
- Conditions
- Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
- Trial name
- NCT04172597
- Testing
- Poziotinib Hydrochloride, Loperamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Fabry Disease
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease
The study will be a randomized, double blind, placebo-controlled study of the safety and efficacy of PRX-102 in ERT naïve male patients randomized 1:1. Patient age will be 14 to 45 years.
- Trial name
- NCT02921620
- Testing
- PRX-102
- Sponsor
- Protalix
Fibrostenotic Crohn's Disease
A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease
This is a Phase 1b, open-label, exploratory study designed to evaluate the pharmacodynamic effects of PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD).
- Trial name
- NCT07428096
- Testing
- PALI-2108
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Palisade Bio
Heartburn
Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn
Remote un-controlled trial to evaluate the tolerability of MHS-1031 and separately the tolerability of the formulated placebo in subjects with heartburn.
- Trial name
- NCT05363618
- Testing
- Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)
- Where
- United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Microbiome Health Sciences
Chronic Hepatitis C, Hepatitis C (HCV)
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
- Trial name
- NCT01464827
- Testing
- ABT-450, ABT-333, ABT-267
- Where
- 97 sites in United States, Australia and 7 more
- Volunteers
- 580 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Advanced Solid Tumor, Metastatic Solid Tumors
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Trial name
- SHIELD-1 (NCT03993873)
- Testing
- elzovantinib (TPX-0022)
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Turning Point Therapeutics, Inc.
Ulcerative Colitis
Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)
The purpose of the protocol is to assess the effectiveness of Etiasa® for preventing relapse in Chinese patients with quiescent UC.
- Trial name
- NCT03689673
- Testing
- Data collection
- Where
- 26 sites in China
- Volunteers
- 607 people
- Sponsor
- Ipsen
Pancreatic Cancer
Study of Ruxolitinib in Pancreatic Cancer Patients
The purpose of this study was to determine whether ruxolitinib added to capecitabine is effective in improving the overall survival of patients with metastatic pancreatic cancer.
- Trial name
- RECAP (NCT01423604)
- Testing
- Capecitabine, Ruxolitinib
- Where
- 39 sites in United States
- Volunteers
- 136 people
- Sponsor
- Incyte Corporation
Ulcerative Colitis
Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
Primary Objective: To assess the long term safety and tolerability of SAR339658 Secondary Objective: To assess the long term efficacy of SAR339658
- Trial name
- NCT01861249
- Testing
- SAR339658
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sanofi
Cystic Fibrosis
An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
This study is designed to evaluate the risk of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of pediatric patients with Cystic Fibrosis who are 11 years…
- Trial name
- NCT01863238
- Testing
- Ophthalmologic examinations, Ivacaftor Exposed
- Where
- 38 sites in United States
- Volunteers
- 95 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Ulcerative Colitis, Gastrointestinal Disease
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis.
- Conditions
- Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
- Trial name
- NCT00073047
- Testing
- Daclizumab
- Where
- 35 sites in United States, Belgium and 1 more
- Volunteers
- 150 people
- Sponsor
- Facet Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.